|
1
|
Vogenberg FR, Barash C Isaacson and Pursel
M: Personalized medicine: Part 1: Evolution and development into
theranostics. P T. 35:560–576. 2010.PubMed/NCBI
|
|
2
|
Vogenberg FR, Barash CI and Pursel M:
Personalized medicine: Part 2: Ethical, legal, and regulatory
issues. P T. 35:624–642. 2010.PubMed/NCBI
|
|
3
|
Sairamesh J and Rossbach M: An economic
perspective on personalized medicine. HUGO J. 7:12013. View Article : Google Scholar
|
|
4
|
Sadée W and Dai Z:
Pharmacogenetics/genomics and personalized medicine. Hum Mol Genet.
14:R207–R214. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tezak Z, Kondratovich MV and Mansfield E:
US FDA and personalized medicine: In vitro diagnostic regulatory
perspective. Per Med. 7:517–530. 2010. View Article : Google Scholar
|
|
6
|
Vu T and Claret FX: Trastuzumab: Updated
mechanisms of action and resistance in breast cancer. Front Oncol.
2:622012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Romero-Otero J, García-Gómez B,
Duarte-Ojeda JM, Rodríguez-Antolín A, Vilaseca A, Carlsson SV and
Touijer KA: Active surveillance for prostate cancer. Int J Urol.
23:211–218. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
El Miedany Y: MABS: Targeted therapy
tailored to the patient's need. Br J Nurs. 24 Suppl 1:S4–S13. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hammerstrom AE, Cauley DH, Atkinson BJ and
Sharma P: Cancer immunotherapy: Sipuleucel-T and beyond.
Pharmacotherapy. 31:813–828. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mali P, Esvelt KM and Church GM: Cas9 as a
versatile tool for engineering biology. Nat Methods. 10:957–963.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cyranoski D: CRISPR gene-editing tested in
a person for the first time. Nature. 539:4792016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Reardon S: First CRISPR clinical trial
gets green light from US panel. Nature News. http://www.nature.com/news/first-crispr-clinical-trial-gets-green-light-from-usupanel-1.20137October
8–2016
|
|
13
|
Kulkarni A and Padilla N: A Strategist's
Guide to Personalized Medicine. Strategy and Business.
75:Summer;2014.2014.
|
|
14
|
Hamburg MA and Collins FS: The path to
personalized medicine. N Engl J Med. 363:301–304. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Association of the British Pharmaceutical
Industry: The stratification of disease for personalised medicines.
http://www.abpi.org.uk/our-work/library/medical-disease/Pages/personalised-medicines.aspxApril
16–2009
|
|
16
|
Wan JCM, Massie C, Garcia-Corbacho J,
Mouliere F, Brenton JD, Caldas C, Pacey S, Baird R and Rosenfeld N:
Liquid biopsies come of age: Towards implementation of circulating
tumour DNA. Nat Rev Cancer. 17:223–238. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jamal-Hanjani M, Hackshaw A, Ngai Y, Shaw
J, Dive C, Quezada S, Middleton G, De Bruin E, Le Quesne J, Shafi
S, et al: Tracking genomic cancer evolution for precision medicine:
The lung TRACERx study. PLoS Biol. 12:e10019062014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hood L and Galas D: The digital code of
DNA. Nature. 421:444–448. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Khoury MJ, Gwinn M, Yoon PW, Dowling N,
Moore CA and Bradley L: The continuum of translation research in
genomic medicine: How can we accelerate the appropriate integration
of human genome discoveries into health care and disease
prevention? Genet Med. 9:665–674. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Snyderman R: The Case for Personalized
Medicine, 201D. 3rd. Washington, DC: pp. 1–32. 2011
|
|
21
|
U.S. Food and drug Administration: Paving
Way for Personalized Medicine: FDA's role in a new era of medical
product development. http://www.fda.gov/downloads/scienceresearch/specialtopics/personalizedmedicine/ucm372421January
10–2014
|
